We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,031

Washington Healthcare Update - Apr 16, 2018
  • McGuireWoods LLP
  • USA
  • April 16 2018

On April 11, Speaker of the House Paul Ryan announced he would not run for re-election to Congress. Already some in the House are suggesting Ryan


Capitol Hill Healthcare Update
  • Baker & Hostetler LLP
  • USA
  • April 9 2018

Lawmakers return today to Capitol Hill after a two-week recess, and multiple committees in both the House and Senate are poised to examine the opioid


Oregon Joins Growing Number of States with New Drug Pricing Transparency Laws
  • Arent Fox LLP
  • USA
  • March 21 2018

Oregon is the latest state to adopt a drug pricing transparency law, following in the footsteps of Vermont, California, Nevada, and Maryland, which


Drug Price Transparency Bill Enacted in Oregon
  • Cooley LLP
  • USA
  • March 14 2018

The Governor of Oregon signed into law this week House Bill 4005, the Prescription Drug Price Transparency Act (Act). The Act requires manufacturers


Drug Costs Targeted in Administration’s Fiscal Year 2019 Budget
  • Cooley LLP
  • USA
  • February 13 2018

Yesterday, the Administration released its Fiscal Year 2019 (FY19) Budget blueprint. The $4.4 trillion Budget blueprint includes several proposals


The Highs Celebrating the Ten Best Prescription DrugMedical Device Decisions of 2017
  • Reed Smith LLP
  • USA
  • December 28 2017

Ending the year on a high note is one thing that the blog tries to do - with the top ten drugdevice product liability decisions of the year


California Passes Two Drug Pricing Transparency Laws
  • Quarles & Brady LLP
  • USA
  • November 20 2017

Last month, California Governor Jerry Brown signed two new bills aimed at curtailing rising prescription drug costs, joining other states like


FTC Holds Public Workshop to Consider If Hatch-Waxman Is Working for Prescription Drug Competition
  • Arent Fox LLP
  • USA
  • November 13 2017

On November 8, 2017, the Federal Trade Commission held a workshop entitled, “Understanding Competition in Prescription Drug Markets: Entry and Supply


West Virginia Plaintiffs Haunted by Past Excesses
  • Reed Smith LLP
  • USA
  • November 13 2017

We remember how, shortly after the atrocious decision in Johnson & Johnson v. Karl, 647 S.E.2d 899 (W. Va. 2007), rejecting altogether the learned


New Report Says Biosimilars Could Save $54 Billion in Biologics Spending
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • November 7 2017

According to a new report by RAND Corporation, biosimilars could save $54 billion in healthcare spending on biologics over the next ten years